Regulatory: Completed MHRA Scientific Advisory Meeting on Derm1 (NG12-2) Prevention of Radiodermatitis Clinical Study Design and Approval Path
Regulatory: Completed MHRA Scientific Advisory Meeting on Derm1 (NG12-2) Prevention of Radiodermatitis Clinical Study Design and Approval Path
10th – June- 2026
VasoDynamics Ltd, the pharmaceutical company developing patient-friendly cost-effective therapies for the prevention/reduction of debilitating side-effects induced by anti-cancer treatments, has completed a successful Scientific Advisory meeting with UK Medicines and Healthcare products Regulatory Agency (MHRA) on 10th June 2026 for Derm1 (NG12-2) to prevent/reduce radiodermatitis. The meeting discussed the planned Phase-3 clinical study design, provided advice on the clinical development plan, and confirmed the market approval path of the innovative dermal topical medicine Derm1 (NG12-2) for the prevention of radiodermatitis in patients undergoing radiotherapy on their head and neck area. The formal written response is expected in July 2026.
To date, VasoDynamics has completed the Scientific Advice meetings on all three of the topical vasoconstriction products currently in the late clinical stage, including Muc1(NG11-2) for the prevention of Radiation-Induced Oral Mucositis, Derm1 (NG12-2) for the prevention of Radiodermatitis, and Derm2 (NG13-2) for the prevention of Chemotherapy-Induced Alopecia.
Dr Ningfeng Fiona Li, Founder and CEO, said:
“We are pleased to have received positive feedback along with supportive advice during a fruitful Scientific Advisory meeting. We appreciate the MHRA granted us this opportunity to discuss the Derm1 Pivotal trial design and for clarifying the approval pathway to bring this innovative product to the market. As a result, we now have a confirmed clear path to bring all three patient-friendly preventive medicine to market to support the cancer therapeutics and the patients with a package of solutions for a better outcome of cancer control.”
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO
fiona.li@vasodynamics.co.uk
Notes to Editors:
About VasoDynamics
VasoDynamics is a clinical-stage pharmaceutical development company based in Stevenage-London, UK, with the vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a portfolio of cost-effective, preventive medicines, which target debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal vs. cancerous vasculature, enabling targeted protection of normal tissue without disrupting the efficacy of anti-cancer treatment, so to improve the safety and effectiveness of cancer treatments and improve the patients’ wellbeing.
